In last trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 2.97 million shares changing hands with its beta currently measuring 1.78. Company’s recent per share price level of $50.43 trading at -$2.59 or -4.88% at ring of the bell on the day assigns it a market valuation of $4.33B. That closing price of CRSP’s stock is at a discount of -80.65% from its 52-week high price of $91.10 and is indicating a premium of 27.58% from its 52-week low price of $36.52.

For CRISPR Therapeutics AG (CRSP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.93. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.28 in the current quarter.

CRISPR Therapeutics AG (NASDAQ:CRSP) trade information

Upright in the red during last session for losing -4.88%, in the last five days CRSP remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $50.43 price level, adding 9.75% to its value on the day. CRISPR Therapeutics AG’s shares saw a change of 28.12% in year-to-date performance and have moved 16.47% in past 5-day. CRISPR Therapeutics AG (NASDAQ:CRSP) showed a performance of 21.49% in past 30-days.

Wall Street analysts have assigned a consensus price target of 67 to the stock, which implies a rise of 24.73% to its current value. Analysts have been projecting 65 as a low price target for the stock while placing it at a high target of 95. It follows that stock’s current price would drop -28.89% in reaching the projected high whereas dropping to the targeted low would mean a loss of -28.89% for stock’s current value.

CRISPR Therapeutics AG (CRSP) estimates and forecasts

This year revenue growth is estimated to rise 59.88% from the last financial year’s standing.

15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 6.67M for the same. And 15 analysts are in estimates of company making revenue of 9.77M in the next quarter. Company posted 504k and 517k of sales in current and next quarters respectively a year earlier.

In 2025, company’s earnings growth rate is likely to be around -10.48% while estimates for its earnings growth in next 5 years are of 24.15%.

CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders

CAPITAL INTERNATIONAL INVESTORS is the top institutional holder at CRSP for having 7.87 million shares of worth $424.8 million. And as of 2024-06-30, it was holding 9.2619 of the company’s outstanding shares.

The second largest institutional holder is ARK INVESTMENT MANAGEMENT LLC, which was holding about 7.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.1597 of outstanding shares, having a total worth of $420.12 million.

On the other hand, ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 6.44 shares of worth $324.61 million or 7.50% of the total outstanding shares. The later fund manager was in possession of 4.79 shares on Dec 31, 2024 , making its stake of worth around $241.62 million in the company or a holder of 5.59% of company’s stock.